768 related articles for article (PubMed ID: 36350491)
21. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
22. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
[TBL] [Abstract][Full Text] [Related]
23. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
[TBL] [Abstract][Full Text] [Related]
24. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
25. Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing-remitting multiple sclerosis patients.
Arisi I; Malimpensa L; Manzini V; Brandi R; Gosetti di Sturmeck T; D'Amelio C; Crisafulli S; Ferrazzano G; Belvisi D; Malerba F; Florio R; Pascale E; Soreq H; Salvetti M; Cattaneo A; D'Onofrio M; Conte A
Front Immunol; 2023; 14():1234869. PubMed ID: 38152407
[TBL] [Abstract][Full Text] [Related]
26. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
27. Early Aggressive Treatment Approaches for Multiple Sclerosis.
Simpson A; Mowry EM; Newsome SD
Curr Treat Options Neurol; 2021; 23(7):19. PubMed ID: 34025110
[TBL] [Abstract][Full Text] [Related]
28. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study.
Hänninen K; Viitala M; Atula S; Laakso SM; Kuusisto H; Soilu-Hänninen M
J Neurol; 2022 Feb; 269(2):913-922. PubMed ID: 34170403
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
30. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
31. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis.
Montgomery SM; Green L; Karoui H; Nicholas R; Loh J
J Med Econ; 2023; 26(1):139-148. PubMed ID: 36546701
[TBL] [Abstract][Full Text] [Related]
32. Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
Lucchetta RC; Tonin FS; Borba HHL; Leonart LP; Ferreira VL; Bonetti AF; Riveros BS; Becker J; Pontarolo R; Fernandez-Llimós F; Wiens A
CNS Drugs; 2018 Sep; 32(9):813-826. PubMed ID: 30014314
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
34. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
35. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis.
Landmeyer NC; Bürkner PC; Wiendl H; Ruck T; Hartung HP; Holling H; Meuth SG; Johnen A
Neurology; 2020 Jun; 94(22):e2373-e2383. PubMed ID: 32430312
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
37. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
38. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
40. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
